ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
1.080
+0.110 (11.33%)
At close: Apr 1, 2026, 4:00 PM EDT
1.010
-0.070 (-6.48%)
Pre-market: Apr 2, 2026, 4:01 AM EDT
ABVC BioPharma Employees
As of December 31, 2025, ABVC BioPharma had 19 total employees, including 16 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$416,240
Market Cap
26.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | 0 | - | 16 | 3 |
| Dec 31, 2024 | 19 | 0 | - | 16 | 3 |
| Dec 31, 2023 | 19 | -4 | -17.39% | 16 | 3 |
| Dec 31, 2022 | 23 | -7 | -23.33% | 19 | 4 |
| Dec 31, 2021 | 30 | -4 | -11.76% | 28 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Senti Biosciences | 34 |
| Boundless Bio | 28 |
| Passage Bio | 24 |
| Daré Bioscience | 23 |
| Quantum BioPharma | 17 |
| NeuroSense Therapeutics | 17 |
| Exicure | 8 |
ABVC News
- 1 year ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 2 years ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 2 years ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 2 years ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire